Thanks, Skorpian. It's important that people be prepared to take a long view with companies like OSL. The analogy with SRX, in product terms, is a good anf valid one. But that need not mean that we can automatically expect to see the company follow exactly the same very successful path trodden by SRX.
Given that OSL is working on what is essentially a new delivery system, for an already-demonstrated treatment, the path to market should be shorter than that for SRX, but that does not mean that we will see proven clinical results next week, or next month, or, perhaps, even next year.
But if, as a result of that testing, people are able to lead longer and better lives, then the OSL principals can rightly be happy with what they have contributed, and shareholders will be rewarded - maybe, even, well-rewarded!
Cheers, Prime1
OSL Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)